Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on kidney disease, has awarded stock options to two new employees as employment inducement grants. The options total 95,100 shares of common stock with an exercise price of $3.14 per share, matching the closing price on August 29, 2025.
The options feature a four-year vesting schedule, with 25% vesting after one year and the remaining 75% vesting quarterly thereafter, contingent on continued employment. The options have a 10-year term and are governed by Akebia's inducement award program and stock option agreements.
Akebia Therapeutics (Nasdaq: AKBA), una società biofarmaceutica specializzata nelle malattie renali, ha assegnato opzioni su azioni a due nuovi dipendenti come incentivi all'assunzione. Le opzioni riguardano in totale 95.100 azioni ordinarie con un prezzo di esercizio di $3,14 per azione, corrispondente al prezzo di chiusura del 29 agosto 2025.
Le opzioni prevedono un piano di vesting quadriennale, con il 25% che matura dopo un anno e il restante 75% che matura trimestralmente successivamente, subordinato alla permanenza in servizio. Le opzioni hanno una durata di 10 anni e sono disciplinate dal programma di incentivi di Akebia e dai relativi accordi sulle opzioni su azioni.
Akebia Therapeutics (Nasdaq: AKBA), una compañía biofarmacéutica centrada en enfermedades renales, ha otorgado opciones sobre acciones a dos nuevos empleados como incentivos de contratación. Las opciones comprenden un total de 95.100 acciones ordinarias con un precio de ejercicio de $3,14 por acción, que coincide con el precio de cierre del 29 de agosto de 2025.
Las opciones incluyen un calendario de adquisición (vesting) de cuatro años, con el 25% que se adquiere después de un año y el 75% restante que se adquiere trimestralmente a partir de entonces, condicionado a la continuidad en el empleo. Las opciones tienen un plazo de 10 años y se rigen por el programa de incentivos de Akebia y los acuerdos de opciones sobre acciones.
Akebia Therapeutics (Nasdaq: AKBA), 신장 질환에 주력하는 바이오제약사인 이 회사는 두 명의 신입 직원에게 고용 유인 목적으로 주식매수선택권을 부여했습니다. 해당 옵션은 총 95,100주의 보통주에 대한 것으로, 행사가격은 주당 $3.14로 2025년 8월 29일 종가와 동일합니다.
옵션은 4년간의 베스팅 일정을 따르며, 1년 후 25%가 베스트되고 나머지 75%는 이후 분기별로 베스트되며 계속 고용 상태에 있는 경우에만 유효합니다. 옵션의 유효기간은 10년이며 Akebia의 유인상 수여 프로그램과 주식매수선택권 계약에 따라 관리됩니다.
Akebia Therapeutics (Nasdaq: AKBA), une société biopharmaceutique spécialisée dans les maladies rénales, a attribué des options d'achat d'actions à deux nouveaux employés à titre d'incitation à l'embauche. Les options portent au total sur 95 100 actions ordinaires avec un prix d'exercice de 3,14 $ par action, correspondant au cours de clôture du 29 août 2025.
Les options comportent un calendrier d'acquisition sur quatre ans, 25 % devenant acquis après un an et les 75 % restants étant acquis trimestriellement par la suite, sous réserve de la poursuite de l'emploi. Les options ont une durée de 10 ans et sont régies par le programme d'attribution incitative d'Akebia et les accords d'options sur actions.
Akebia Therapeutics (Nasdaq: AKBA), ein biopharmazeutisches Unternehmen mit Fokus auf Nierenerkrankungen, hat zwei neuen Mitarbeitern als Anstellungsanreiz Aktienoptionen gewährt. Die Optionen umfassen insgesamt 95.100 Stammaktien mit einem Ausübungspreis von $3,14 je Aktie, entsprechend dem Schlusskurs vom 29. August 2025.
Die Optionen sehen einen Vesting-Zeitraum von vier Jahren vor: 25% werden nach einem Jahr fällig, die verbleibenden 75% jeweils vierteljährlich danach, vorbehaltlich fortgesetzter Beschäftigung. Die Optionen haben eine Laufzeit von 10 Jahren und unterliegen Akebias Incentive-Programm sowie den entsprechenden Aktienoptionsverträgen.
- None.
- None.
CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted two newly-hired employees options to purchase an aggregate of 95,100 shares of Akebia’s common stock on August 29, 2025. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
FAQ
What type of stock options did Akebia Therapeutics (AKBA) grant to new employees in August 2025?
What is the vesting schedule for Akebia Therapeutics' (AKBA) August 2025 employee stock options?
Why did Akebia Therapeutics (AKBA) issue these stock options in August 2025?
What is the exercise price of Akebia Therapeutics' (AKBA) August 2025 inducement grants?
